Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | New promise in treating mBC: combining anti-AR therapy with chemotherapy

Shilpa Gupta • 15 Feb 2019
GU Cancers 2019
Bladder Cancer Genitourinary Cancer Cisplatin Enzalutamide Gemcitabine

Here, Shilpa Gupta, MD, of the University of Minnesota, Minneapolis, MN, presents promising results from a Phase I trial (NCT02300610) investigating the combined use of enzalutamide with gemcitabine and cisplatin in metastatic bladder cancer (mBC). This video was taken at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Shilpa Gupta

1:11
The optimal sequence of ADCs and other therapies in advanced and metastatic urothelial cancer
Shilpa Gupta • 3 Jun 2023
1:02
The role of EV and pembrolizumab in the urothelial carcinoma treatment landscape
Shilpa Gupta • 3 Jun 2023
6:02
EV-103: EV + pembrolizumab as a promising first-line option for urothelial carcinoma
Shilpa Gupta • 3 Jun 2023
2:06
MAIN-CAV: maintenance cabozantinib and avelumab in urothelial cancer
Shilpa Gupta • 3 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals